Neuraxis inc NRXS.US 總覽分析
)NRXS 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
NRXS 近期報酬表現
-11.64%
Neuraxis inc
1.99%
同產業平均
-0.64%
S&P500
與 NRXS 同產業的標的表現
- NNOX Nano-x imaging ltd價值 3 分趨勢 3 分波段 2 分籌碼 1 分股利 1 分查看更多
NRXS 公司資訊
Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company's second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient's ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.